Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.0800 (-0.97%) ($5.0400 - $5.0800) on Fri. Jul. 16, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.57% (three month average) | RSI | 46 | Latest Price | $5.0800(-0.97%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -1% a day on average for past five trading days. | Weekly Trend | ADMS declines -1.7% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) PEJ(7%) SMH(80%) REMX(9%) SDY(4%) SIL(40%) | Factors Impacting ADMS price | ADMS will decline at least -1.785% in a week (0% probabilities). XRT(17%) IWD(16%) IWC(17%) IBB(70%) JETS(3%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.785% (StdDev 3.57%) | Hourly BBV | 0.3 () | Intraday Trend | 0% | | | |
|
Resistance Level | $5.28 | 5 Day Moving Average | $5.15(-1.36%) | 10 Day Moving Average | $5.28(-3.79%) | 20 Day Moving Average | $5.28(-3.79%) | To recent high | -13.5% | To recent low | 1.4% | Market Cap | $144m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |